Company repurchased 7,500,000 shares of its common stock from Matrix at $1.33 per share under a Stock Purchase Agreement
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Julie Eastland
Also a director
President, Chief Executive Officer and Director
|
62 | Not stated | $1,300,731 | |
|
Ingmar Bruns
Chief Medical Officer
|
51 |
Since 2024
2 years
|
$869,843 | |
|
James Bucher
Chief Legal Officer and Corporate Secretary
|
60 |
Since 2025
1 year
|
$659,973 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 30, 2026 · updated by the 8-K of May 27, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Scott Myers
Board chair
|
60 |
2024
2 years
|
Independent |
Compensation
Nominating and Corporate Governance
|
None stated | $184,136 | |
|
Julie Eastland
CEO
|
62 |
2024
2 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
David Johnson
|
61 |
2020
6 years
|
Independent |
Compensation · Chair
|
Aura (Nasdaq: AURA) | $139,251 | |
|
Jan Skvarka, Ph.D.
|
59 |
2022
4 years
|
Independent |
Audit
Nominating and Corporate Governance · Chair
|
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) | $151,405 | |
|
Enoch Kariuki, Pharm.D.
|
44 |
2021
5 years
|
Not stated | None stated | None stated | $151,405 | |
|
Luke Walker, M.D.
|
54 |
2024
2 years
|
Independent |
Audit
Nominating and Corporate Governance
|
Context Therapeutics Inc. (Nasdaq: CNTX) | $145,266 | |
|
Shannon Campbell
Joined May 22, 2026
|
- | - | - |
Compensation Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Company repurchased 7,500,000 shares of its common stock from Matrix at $1.33 per share under a Stock Purchase Agreement
License agreement under which Zeno Pharmaceuticals, Inc. was granted an exclusive worldwide license; Gallagher is a managing member of and holds an ownership interest in Recurium IP; zero milestone fees paid to Recurium IP
Loading...